Terminology Service < Semantic Lookup Platform

All terms in MESH

Label	Id	Description
S27847	C512501
CRYBB1 protein, human	C105601
2-methyl-3-(2-(1,2,3,4-tetrahydrobenzo(4,5)furo(3,2-c)pyridin-2-yl)ethyl)-4H-pyrido(1,2-a)pyrimidin-4-one	C512502
3-glucosido-chenodeoxycholic acid	C105602
MLL-SEPT6 fusion protein, human	C512503
3-glucosido-lithocholic acid	C105603
Leu-Ala hydroxyethylene	C512504
N'-((4S,5S,7R)-7-(isobutylcarbamoyl)-5-hydroxy-2-methyloctan-4-yl)-N-((R)-1-hydroxy-3-methylbutan-2-yl)5-nitrobenzene-1,3-diamide	C512505
N'-((4S,5S,7R)-7-(isobutylcarbamoyl)-5-hydroxy-2-methyloctan-4-yl)-N-((S)-1-hydroxy-3-methylbutan-2-yl)5-(methyl(methylsulfonyl)amine)benzene-1,3-diamide	C512506
phospholipase D2	C105606
PlsB protein, E coli	C512507
dehydroquinate dehydratase-skikimate dehydrogenase, Arabidopsis	C512508
beta-phosphoglucomutase, Lactococcus lactis	C512509
gRICH68 protein, Carassius auratus	C105609
Antineoplastic Combined Chemotherapy Protocols	D000971	[The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.]
Drug Therapy, Combination	D004359	[Therapy with two or more separate preparations given for a combined effect.]
Antineoplastic Protocols	D024221	[Clinical protocols used to inhibit the growth or spread of NEOPLASMS.]
Antineoplastic Agents, Phytogenic	D000972	[Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.]
Antibodies, Antinuclear	D000974	[Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.]
Autoantibodies	D001323	[Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.]